Yamanaka H
Department of Urology, Gunma University School of Medicine, Maebashi 371-8511.
Rinsho Byori. 2001 Jul;49(7):633-7.
Prostate cancer and benign prostatic hyperplasia(BPH) are common diseases of in elderly men. Prostate cancer is a leading cause of morbidity and mortality in men in western countries. In Japan, especially, prostate cancer deserves our attention, because Japan has already become one of the most rapidly aging societies in the world. The morbidity and mortality rates of prostate cancer in Japan are now increasing steadily in recent years, although those rates are still very low compared with the rates in western countries. Fortunately, an excellent tumor marker, PSA, is available to detect early stage prostate cancer. In Gunma prefecture, we started mass screening for prostate cancer in the Ohta district(one city, three towns and one village) in 1981. In 2000, 36 of 70 cities, towns, and villages conducted mass screening for prostate cancer. We obtained the important results from long-term follow-up of mass screening for prostate cancer in Gunma prefecture. That is, patients who were detected by mass screening were in an earlier stage and survived longer than patients who were found out in hospitals. Lastly, I present the report of the PSA Ad Hoc Committee of the Japanese Urological Association in 2000.
前列腺癌和良性前列腺增生（BPH）是老年男性的常见疾病。前列腺癌是西方国家男性发病和死亡的主要原因之一。特别是在日本，前列腺癌值得我们关注，因为日本已经成为世界上老龄化速度最快的社会之一。近年来，日本前列腺癌的发病率和死亡率虽仍远低于西方国家，但呈稳步上升趋势。幸运的是，一种出色的肿瘤标志物——前列腺特异性抗原（PSA）可用于检测早期前列腺癌。1981年，我们在群马县大田地区（一个市、三个镇和一个村）开始了前列腺癌的大规模筛查。2000年，70个市、镇和村中有36个开展了前列腺癌的大规模筛查。我们从群马县前列腺癌大规模筛查的长期随访中获得了重要结果。也就是说，通过大规模筛查发现的患者处于更早阶段，并且比在医院发现的患者存活时间更长。最后，我介绍日本泌尿外科学会2000年PSA特别委员会的报告。
